MedTrace Logo

The Pregnancy 24/7 Cohort Study

NCT04749849 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-05-23

No results posted yet for this study

Summary

Moderate to vigorous intensity physical activity is known to reduce the risk of hypertensive disorders of pregnancy and other adverse pregnancy outcomes that increase future maternal cardiovascular disease risk (2018 Physical Activity Guidelines Advisory Committee, 2018; Davenport et al., 2018), yet less than 25% of pregnant women meet public health physical activity guidelines (Hesketh \& Evenson, 2016). More than 95% of the 24-hour day is spent in sedentary behavior, sleep, or light-intensity activity; however, the impacts of these lower intensity activities on adverse pregnancy outcomes are unknown. This multi-site observational cohort study (N=500) will leverage state-of-the-art, 24-hour behavior assessment in each trimester of pregnancy and examine associations with adverse pregnancy outcomes to inform guidelines and future interventions designed to improve women's pregnancy and long-term cardiovascular health.

Conditions

  • Healthy

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of Pittsburgh

    collaborator OTHER

  • West Virginia University

    collaborator OTHER

  • Kara Whitaker

    lead OTHER

Principal Investigators

  • Kara Whitaker, PhD, MPH · University of Iowa

  • Bethany Barone Gibbs, PhD · West Virginia University

  • Christopher Kline, PhD · University of Pittsburgh

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2025-02-18
Completion
2025-04-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04749849 on ClinicalTrials.gov